Sei Investments Co. Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK

Sei Investments Co. increased its position in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 18.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 143,359 shares of the company’s stock after buying an additional 22,832 shares during the period. Sei Investments Co.’s holdings in Scholar Rock were worth $7,047,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. IFP Advisors Inc grew its position in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Scholar Rock during the 4th quarter valued at approximately $30,000. Summit Securities Group LLC bought a new stake in shares of Scholar Rock during the fourth quarter valued at approximately $31,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares in the last quarter. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Scholar Rock in the fourth quarter worth $44,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Trading Down 3.0%

Shares of NASDAQ SRRK opened at $45.85 on Tuesday. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $58.49. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. The business’s 50 day moving average is $50.06 and its two-hundred day moving average is $47.74. The stock has a market capitalization of $5.49 billion, a P/E ratio of -12.77 and a beta of 0.69.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter last year, the company earned ($0.67) earnings per share. As a group, research analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Insider Activity at Scholar Rock

In other Scholar Rock news, Director Kristina Burow sold 3,053 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the transaction, the director directly owned 114,657 shares of the company’s stock, valued at $6,161,667.18. The trade was a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the sale, the director directly owned 27,856 shares in the company, valued at approximately $1,500,881.28. This represents a 9.88% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 17,149 shares of company stock valued at $923,108 over the last three months. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

SRRK has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Friday, July 17th. Barclays boosted their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Wedbush reissued an “outperform” rating and set a $58.00 price objective on shares of Scholar Rock in a report on Tuesday, July 21st. Canaccord Genuity Group assumed coverage on Scholar Rock in a report on Monday, April 20th. They set a “buy” rating and a $62.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $56.21.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).